首页> 外文期刊>Bone marrow transplantation >Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
【24h】

Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)

机译:同种异体造血干细胞移植后自身免疫性细胞分开(AIC)用于获得的血栓性贫血:欧洲血液和骨髓移植社会自身免疫性疾病和严重血栓性贫血工作缔约方(ADWP / SAAWP)的联合研究(EBMT)

获取原文
获取原文并翻译 | 示例
       

摘要

This retrospective study explored the incidence of autoimmune cytopenia (AIC) in 530 paediatric and adult patients with acquired aplastic anaemia (aAA) who underwent first allogeneic HSCT between 2002 and 2012. AIC was a rare complication with a cumulative incidence of AIC at 1, 3, 5 and 10 years post HSCT of 2.5% (1.2-3.9 95% CI), 4.4% (2.6-6.2 95% CI), 4.6% (2.8-6.5 95% CI) and 5.1% (3.1-7.2 95% CI). Overall survival at 5 years after diagnosis of AIC was 85.9% (71-100 95% CI). Twenty-five patients were diagnosed with AIC at a median of 10.6 (2.6-91.5) months post HSCT. Eight (32%) patients were diagnosed with immune thrombocytopenia (ITP), seven (28%) with autoimmune haemolytic anaemia (AIHA), seven (24%) with Evans syndrome and four (16%) with autoimmune neutropenia (AIN). Treatment strategies were heterogeneous. Complete responses were seen in 12 of 25 patients, with death in three patients. In multivariable Cox analysis of a subgroup of 475 patients, peripheral blood stem cell (PBSC) transplant was associated with higher risk of AIC compared with bone marrow (BM) when conditioning regimens contained fludarabine and/or alemtuzumab (2.81 [1.06-7.49 95% CI]; p = 0.038), or anti-thymocyte globulin (ATG) (2.86 [1.11-7.37 95% CI]; p = 0.029). Myeloablative conditioning was associated with a lower risk of AIC compared with reduced intensity conditioning (RIC) in fludarabine and/or alemtuzumab (0.34 [0.12-0.98 95% CI]; p = 0.046) and ATG containing regimens (0.34 [0.12-0.95 95% CI]; p = 0.04). These findings provide clinically useful information regarding the incidence of a rare and potentially life-threatening complication of allogeneic HSCT for aAA, and further support for BM as the preferred stem cell source for transplant of patients with aAA.
机译:该回顾性研究探讨了530名儿科和成年患者的自身免疫细胞缺乏症(AIC)的发病率为2002年至2012年间的第一次同种异体贫血(AAA)。AIC是一种罕见的并发症,在1,3的AIC累积发病率,5至10年后HSCT 2.5%(1.2-3.9 95%CI),4.4%(2.6-6.2 95%CI),4.6%(2.8-6.5 95%CI)和5.1%(3.1-7.2 95%CI )。 AIC诊断后5年的整体存活率为85.9%(71-100 95%CI)。在HSCT后中位数诊断为10.6(2.6-91.5)个月的AIC患者。八(32%)患者被诊断为免疫血小板减少症(ITP),7(28%),具有自身免疫溶血性贫血(AIHA),七(24%),evans综合征和四(16%),具有自身免疫性血症(AIN)。治疗策略是异质的。在25名患者中有12名,三名患者死亡,可以看到完整的反应。在475名患者的亚组的多变量COX分析中,当调理方案含有氟氮胺胺和/或Alemtuzumab(2.81 [1.06-7.49 95%95%95%95%95%9.5% CI]; P = 0.038)或抗胸腺细胞球蛋白(ATG)(2.86 [1.11-7.37 95%CI]; P = 0.029)。与氟甲滨岛和/或Alemtuzumab中的强度调理(RIC)相比,髓鞘性调理与较低的AIC风险有关(0.34 [0.34 [0.12-0.98 95%CI]; P = 0.046)和ATG含有方案(0.34 [0.12-0.95 95 %ci]; p = 0.04)。这些发现提供了关于AAA的异种HSCT的罕见和潜在危及危及危及生命并发症的临床有用的信息,以及进一步支持BM作为AAA患者移植的优选干细胞源。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号